Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

D. De; A. Kaushik; S. Handa; R. Mahajan; E. Schmidt

doi:10.1111/jdv.17229

Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

D. De^*, A. Kaushik, S. Handa, R. Mahajan, E. Schmidt

^*Corresponding author for this work

Institute of Experimental Dermatology

Postgraduate Institute of Medical Education and Research

21 Citations (Scopus)

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	35
Issue number	7
Pages (from-to)	e469-e472
Number of pages	4
ISSN	0926-9959
DOIs	https://doi.org/10.1111/jdv.17229
Publication status	Published - 07.2021

Funding

The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, Lübeck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1111/jdv.17229

Cite this

@article{536609ecbfca4cd88980a7e9085fb3e6,

title = "Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities",

author = "D. De and A. Kaushik and S. Handa and R. Mahajan and E. Schmidt",

note = "Funding Information: The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. Funding Information: The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L{\"u}beck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases ",

year = "2021",

month = jul,

doi = "10.1111/jdv.17229",

language = "English",

volume = "35",

pages = "e469--e472",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "John Wiley and Sons Inc",

number = "7",

}

TY - JOUR

T1 - Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

AU - De, D.

AU - Kaushik, A.

AU - Handa, S.

AU - Mahajan, R.

AU - Schmidt, E.

N1 - Funding Information: The study was supported in part by structural funds of the Clinical Research Unit Pemphigoid Diseases (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, L?beck, for excellent technical assistance with the IgE-specific BP180 and BP230 ELISA. Funding Information: The study was supported in part by structural funds of the Clinical Research Unit (KFO 303) and the Cluster of Excellence Precision Medicine in Chronic Inflammation (EXC 2167) both funded by Deutsche Forschungsgemeinschaft. We are grateful to Ms Shilpa for immunological investigations and Vanessa Krull, Lübeck, for excellent technical assistance with the IgE‐specific BP180 and BP230 ELISA. Pemphigoid Diseases

PY - 2021/7

Y1 - 2021/7

UR - https://www.scopus.com/pages/publications/85103202558

UR - https://www.mendeley.com/catalogue/ffff6a1e-5921-334a-8cfb-40e4f9018aaa/

U2 - 10.1111/jdv.17229

DO - 10.1111/jdv.17229

M3 - Letters

C2 - 33725360

AN - SCOPUS:85103202558

SN - 0926-9959

VL - 35

SP - e469-e472

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 7

ER -

Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities

Funding

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Cite this